Stephanie J. Nahas, MD


Discussing Preventative Migraine Lifestyle Changes with Patients

Dr Andrew Charles shares how he eases patient anxieties over lifestyle changes for preventive migraine therapy.

Meilan Rutter, MD


Early Monitoring and Treatment for Bone Health in Duchenne Muscular Dystrophy: Meilan Rutter, MD

At the 2023 MDA conference, a pediatric endocrinologist from Cincinnati Children’s Hospital talked about the unmet needs in treating bone health for patients with Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]

Paige Sutton, MD


Emerging Approaches to the Treatment of Multiple Sclerosis

Experts share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.

Katelynn Getchell


Promising Disease-Modifying Therapies in Parkinson Disease

Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.

Barbara G. Vickrey, MD, MPH


AUPN Leadership Minute Episode 13: Principles of Making a Business Case

Episode 13 of the AUPN Leadership Minute features Muhammad “Mud” Alvi, MD, of West Virginia University; and Barbara G. Vickrey, MD, MPH, of Icahn School of Medicine at Mount Sinai. [WATCH TIME: 4 minutes]

Brent Vaughan


Reviewing the Phase 2 OVERTURE Results of Gamma Sensory Stimulation Device: Brent Vaughan

The chief executive officer of Cognito Therapeutics detailed clinical findings from the open-label extension of the phase 2 OVERTURE study presented at the recent Clinical Trials on Alzheimer’s Disease conference. [WATCH TIME: 4 minutes]

Paul Lipkin, MD


Future Implications, Outlook of New CDC Developmental Milestone Guidelines: Paul Lipkin, MD

The director of medical outpatient services at the Kennedy Krieger Institute discussed the long-term effects of the updated developmental milestone guidelines and the need to judge children based on the 75th percentile. [WATCH TIME: 7 minutes]

Alvaro Pascual-Leone, MD, PhD


Changes in Vocation as Early Signs for Alzheimer Disease, Cognitive Issues: Alvaro Pascual-Leone, MD, PhD

The chief medical officer and cofounder of Linus Health discussed how changes in voice may help serve as early indicators for late-life cognitive deficits. [WATCH TIME: 3 minutes]

Stephan A. Mayer, MD, FCCM, FNCS


A Call for Urgent Action to Redefine Stroke Protocols: Stephan A. Mayer, MD, FCCM, FNCS

The director of neurocritical care and emergency neurology services at Westchester Medical Center Health System talked about a recently published paper that highlighted the need to address the disparity in quality metrics for stroke care, especially for intracerebral hemorrhage. [WATCH TIME: 4 minutes]

Elia Pestana-Knight, MD


Next Steps in Tackling CDKL5 Deficiency Disorder Following First Approval: Elia Pestana-Knight, MD

The pediatric epileptologist from Cleveland Clinic provided commentary on the changes needed to improve research and drug development in CDKL5 deficiency disorder, as well as the organizations committed to advancing the state of care. [WATCH TIME: 3 minutes]

Douglas A. Wajda, PhD


Using the Cionic Neural Sleeve to Alleviate Gait Dysfunction in Multiple Sclerosis: Douglas A. Wajda, PhD

The assistant professor of neurology at Cleveland State University provided perspective on an early-stage study assessing the impacts of a functional electrical stimulation approach to treat gait problems in multiple sclerosis. [WATCH TIME: 4 minutes]

Becca Lassell, PhD, OTR


Applying the Innovation Biodesign Framework to Promote Equity and Green Activity in Dementia Care

Lassell et al present a use case demonstrating the process of moving an unmet need to the “solution space” of the Innovation Biodesign Framework for addressing a healthcare challenge in a specific at-risk population: Alzheimer disease and AD-related dementias.

Rajeev Kumar, MD


Targeting Neuroinflammation in Huntington Disease: Rajeev Kumar, MD

The medical director of the Rocky Mountain Movement Disorders Center talked about the motivations of the phase 2 study on ANX005 for Huntington disease at the 2023 AAN Annual Meeting. [WATCH TIME: 3 minutes]

Benzi Kluger, MD, MS


Expanding Neuropalliative Care to New Disease States: Benzi Kluger, MD, MS

The president of the International Neuropalliative Care Society detailed potential disease states that could benefit from neuropalliative care as well as the importance of the patient community in expanding this type of approach. [WATCH TIME: 4 minutes]

Ehud Marom


Effectiveness and Promise of Glatiramer Acetate Depot in Progressive Multiple Sclerosis: Ehud Marom

The president and chief executive officer of Mapi Pharma discussed the positive phase 2 findings of a new formulation of glatiramer acetate to treat progressive forms of MS, as well as the long-term plans for the drug. [WATCH TIME: 5 minutes]

Ashley Asti


Not Your Grandmother’s Dopamine: PMD Alliance Releases On-Demand CME Topics in Advanced Therapeutics in Movement-Related Disorders

The PMD Alliance has developed a group of 6 on-demand CME events and live panel discussions, in partnership with MedStar Georgetown University Hospital, taking place on October 23-24, 2021, developed and presented by Yasar Torres-Yaghi, MD , and Fernando Pagan, MD.

Kenneth Baker, PhD


Capabilities of Deep Brain Stimulation to Modulate Late-Stage Neuroplasticity: Kenneth Baker, PhD

The associate staff member in the department of neurology at Cleveland Clinic discussed the major take-home points and post-hoc findings from a positive study of deep brain stimulation in poststroke patients. [WATCH TIME: 3 minutes]

Monica Verduzco-Gutierrez, MD


Consensus Guidelines for Spasticity Assessment and Management: Monica Verduzco-Gutierrez, MD

The professor and chair of rehabilitation medicine at UT Health San Antonio talked about the newly published guidelines for the assessment and management of spasticity in patients with neurological conditions. [WATCH TIME: 5 minutes]

Killian Meara


FDA to Add Warning Related to Guillain-Barré Syndrome on Johnson & Johnson Vaccine

Since vaccine administration, the CDC has announced 100 preliminary cases of Guillain-Barré syndrome.

Neepa J. Patel, MD


A Team Approach to Asleep Deep Brain Stimulation

Henry Ford Health System’s investment in advanced DBS technology and its commitment to multidisciplinary care has helped them become a leading treatment center for Parkinson disease and related movement disorders.

Yannick J. Wadop Ngouongo, PhD


Assessing the Impact of Gut Microbiota on Neuroprotection in Alzheimer Disease: Yannick J. Wadop Ngouongo, PhD

The postdoctoral researcher at The University of Texas Health Science Center at San Antonio talked the gut microbiome and neurological disorders, focusing on the potential role of gut microbiota imbalance in the pathogenesis of conditions like Alzheimer disease. [WATCH TIME: 5 minutes]

David B. Watson, MD


AUPN Leadership Minute Episode 38: Visa Issues for Faculty

Episode 38 of the AUPN Leadership Minute features Muhammad "Mud" Alvi, MD, of West Virginia University Robert C. Byrd Health; and David B. Watson, MD, of West Virginia University Robert C. Byrd Health. [WATCH TIME: 5 minutes]

Daria Trojan, MD, MSc


Effects of Long-term CPAP Therapy in Multiple Sclerosis: Daria Trojan, MD, MSc

The associate professor in the department of neurology and neurosurgery at McGill University discussed results from a study on the long-term use of continuous positive airway pressure treatment among patients with multiple sclerosis and sleep apnea presented at MSMilan 2023. [WATCH TIME: 5 minutes]

Luke Lovelace


Promising Disease-Modifying Therapies in Parkinson Disease

Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.

Rodrigo de Holanda Mendonça, MD


Key Considerations in Treatment of Spinal Muscular Atrophy / Considerações essenciais para o tratamento da atrofia muscular espinhal

The expert panel shares clinical pearls for treatment and management of Spinal Muscular Atrophy. O painel de especialistas compartilha recomendações valiosas para o tratamento e manejo da atrofia muscular espinhal.

Pierre Tariot, MD


Aducanumab’s Implications for Future Clinical Trials: Pierre N. Tariot, MD

In addition to his work study pimavanserin in treating dementia-related psychosis, the director of the Banner Alzheimer’s Institute commented on the potential for aducanumab in Alzheimer disease.

Stephen From


Challenges With Addressing Neurodegeneration in Poststroke Patients: Stephen From

The chief executive officer of Aruna Bio discussed the reasons for the failure of neuroprotective agents in ischemic stroke trials and why AB126 has potential to restore neurodegeneration in such affected patients. [WATCH TIME: 3 minutes]

Ye Vivian Liang, MD, PhD


Changes in Presentation of Spasticity Over Time

The expert panel examines the evolution of moderate to severe spasticity following injury or insult, focusing on alterations in joint mobility, changes in range of motion from early to later stages, and other progressive manifestations of the condition.

Hermona Soreq, PhD


Role of Cholinergic Transcripts in Sex-Specific Declines of Alzheimer Disease: Hermona Seroq, PhD

The professor of molecular neuroscience at the Edmond and Lily Safra Center for Brain Sciences discussed the premise behind a study of RNA-sequencing data to better understand the reasons why females suffer accelerated dementia. [WATCH TIME: 9 minutes]

Ihtsham ul Haq, MD, FAAN


Trends in Movement Disorder Research: Ihtsham ul Haq, MD, FAAN

The chief of Movement Disorders Division at the University of Miami Miller School of Medicine discussed some of the recent focused efforts to uncover more about Parkinson disease and what is on the horizon.

© 2024 MJH Life Sciences

All rights reserved.